{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:08:37Z","timestamp":1781309317925,"version":"3.54.1"},"reference-count":18,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,9]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>If clinical trials measure and report the outcomes included in core outcome sets (COS) for a given condition\/disease as a minimum, this has the potential to improve comparability between trials and prevent research waste. Until now, the uptake of the Bronchiectasis and Hidradenitis Suppurativa (HS) COS has not been assessed.<\/jats:p>\n                    <jats:p>This study assessed the uptake of Bronchiectasis and HS COS using a review of trial registries, with entries taken from ClinicalTrials.gov and the WHO International Clinical Trial Registry Platform. This uptake assessment provides valuable information to inform COS refinement and uncover areas lacking uptake to inform further dissemination requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For each trial, the outcomes included in the trial registry entry were extracted and compared with those included in the corresponding Bronchiectasis or HS COS. The Bronchiectasis COS consists of 18 outcomes, and the HS COS, 6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the trials registered after both COS were developed in 2018, 63% (12\/19) of HS trials planned to measure the full COS, whereas for Bronchiectasis, 0% (0\/24) of trials planned to measure the full COS. However, of the five priority outcomes to be measured for Bronchiectasis, 4% (1\/24) of trials planned to measure all five outcomes.<\/jats:p>\n                    <jats:p>Both COS publications\u2019 focus was to reach consensus on what outcomes should be measured. Despite both publications referring to the Core outcome Measures for Effectiveness Trials (COMET) Handbook, which discusses the importance of COS dissemination, implementation plans were not included in either publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results suggest that uptake of the HS COS is relatively good, despite yearly fluctuations, whereas for Bronchiectasis, COS uptake is limited. Further research into standardised measurement tools for HS is expected to increase uptake. The focus for Bronchiectasis, however, will be to refine the COS for feasible application in clinical trials. Future COS development publications should use all resources from the COMET initiative to ensure feasible dissemination of the COS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-095190","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T04:05:25Z","timestamp":1755576325000},"page":"e095190","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing 5-year follow-up of core outcome set uptake for Bronchiectasis and Hidradenitis Suppurativa: a review of trial registry entries"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7365-7804","authenticated-orcid":false,"given":"Charlotte","family":"Shorey","sequence":"first","affiliation":[{"name":"University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-6636","authenticated-orcid":false,"given":"Paula R","family":"Williamson","sequence":"additional","affiliation":[{"name":"Health Data Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-3337","authenticated-orcid":false,"given":"Susanna","family":"Dodd","sequence":"additional","affiliation":[{"name":"Health Data Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"2025123106464632000_15.8.e095190.1","doi-asserted-by":"crossref","unstructured":"Williamson PR , Altman DG , Blazeby JM , et al . Developing core outcome sets for clinical trials: issues to consider. Trials 2012;13. doi:10.1186\/1745-6215-13-132","DOI":"10.1186\/1745-6215-13-132"},{"key":"2025123106464632000_15.8.e095190.2","unstructured":"COMET Initiative . Core outcome measures in effectiveness trials. Available: https:\/\/www.comet-initiative.org\/Resources [Accessed 14 Jun 2025]."},{"key":"2025123106464632000_15.8.e095190.3","doi-asserted-by":"crossref","unstructured":"Williamson PR , Altman DG , Bagley H , et al . The COMET handbook: version 1.0. Trials 2017;18. doi:10.1186\/s13063-017-1978-4","DOI":"10.1186\/s13063-017-1978-4"},{"key":"2025123106464632000_15.8.e095190.4","doi-asserted-by":"crossref","unstructured":"Dwan K , Altman DG , Arnaiz JA , et al . Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 2008;3. doi:10.1371\/journal.pone.0003081","DOI":"10.1371\/journal.pone.0003081"},{"key":"2025123106464632000_15.8.e095190.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.09.029"},{"key":"2025123106464632000_15.8.e095190.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.06.016"},{"key":"2025123106464632000_15.8.e095190.7","doi-asserted-by":"crossref","unstructured":"Spargo M , Ryan C , Downey D , et al . Development of a core outcome set for trials investigating the long-term management of bronchiectasis. Chron Respir Dis 2019;16. doi:10.1177\/1479972318804167","DOI":"10.1177\/1479972318804167"},{"key":"2025123106464632000_15.8.e095190.8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025123106464632000_15.8.e095190.9","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S156279"},{"key":"2025123106464632000_15.8.e095190.10","doi-asserted-by":"crossref","unstructured":"Kirkham JJ , Davis K , Altman DG , et al . Core outcome set-STAndards for development: the COS-STAD recommendations. PLoS Med 2017;14. doi:10.1371\/journal.pmed.1002447","DOI":"10.1371\/journal.pmed.1002447"},{"key":"2025123106464632000_15.8.e095190.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.10.012"},{"key":"2025123106464632000_15.8.e095190.12","doi-asserted-by":"crossref","unstructured":"Kirkham JJ , Clarke M , Williamson PR . A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. BMJ 2017;357. doi:10.1136\/bmj.j2262","DOI":"10.1136\/bmj.j2262"},{"key":"2025123106464632000_15.8.e095190.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.12.020"},{"key":"2025123106464632000_15.8.e095190.14","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0161-2019"},{"key":"2025123106464632000_15.8.e095190.15","doi-asserted-by":"crossref","unstructured":"Hnin K , Nguyen C , Carson KV , et al . Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst Rev 2015;2015. doi:10.1002\/14651858.CD001392.pub3","DOI":"10.1002\/14651858.CD001392.pub3"},{"key":"2025123106464632000_15.8.e095190.16","article-title":"Interventions for hidradenitis suppurativa","volume":"2017","author":"Ingram","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025123106464632000_15.8.e095190.17","unstructured":"HiSTORIC: hidradenitis suppurativa core outcomes set international collaboration. Available: https:\/\/www.c3outcomes.org\/historic [Accessed 14 Jun 2025]."},{"key":"2025123106464632000_15.8.e095190.18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jclinepi.2019.07.007","article-title":"Industry funding was associated with increased use of core outcome sets","volume":"115","author":"Kirkham","year":"2019","journal-title":"J Clin Epidemiol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-095190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:48:14Z","timestamp":1767192494000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-095190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,18]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2024-095190"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095190","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}